| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23004 |
| Drug | Ropeginterferon alfa-2b |
| Brand | Besremi® |
| Indication | Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
| Assessment Process | |
| Rapid review commissioned | 20/01/2023 |
| Rapid review completed | 15/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/03/2023 |
| Pre-submission consultation with Applicant | 03/05/2023 |
| Full submission received from Applicant | 20/07/2023 |
| Preliminary review sent to Applicant | 27/11/2023 |
| NCPE assessment re-commenced | 03/01/2024 |
| Factual accuracy sent to Applicant | 26/06/2024 |
| NCPE assessment re-commenced | 15/07/2024 |
| NCPE assessment completed | 15/08/2024 |
| NCPE assessment outcome | The NCPE recommends that ropeginterferon alfa-2b (Besremi®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.